metaLead Therapeutics is to develop this peptide as a next-generation Pb poisoning treatment.
metaLead Therapeutics has raised $1.2M in total funding. The most recent round was Seed. The last funding was announced in May 2025.
metaLead Therapeutics's investors include BioInnovation Institute, Venture Kick, UZH Life Sciences Fund.
metaLead Therapeutics is headquartered in Zürich, Switzerland.
metaLead Therapeutics is to develop this peptide as a next-generation Pb poisoning treatment.
metaLead Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"metaLead Therapeutics — Funding & Investors." VCBacked, May 6, 2025, https://www.vcbacked.co/company/metalead-therapeutics. Accessed August 14, 2026.
VCBacked. (2025). metaLead Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/metalead-therapeutics
{{cite web |title=metaLead Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/metalead-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated